Finerenone Achieves Primary Endpoint in FIND-CKD Phase III Study for Non-Diabetic CKD

Finerenone has met its primary endpoint in the pivotal Phase III FIND-CKD study, demonstrating significant efficacy for patients with non-diabetic chronic kidney disease. These results underscore finerenone’s potential to expand therapeutic options in CKD beyond the diabetic population.

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.